Table 1 Clinical characteristics of the study population
From: Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial
Enoxaparin dose | 40 mg (n = 18) | 50 mg (n = 16) | 60 mg (n = 20) | 70 mg (n = 18) | p |
|---|---|---|---|---|---|
Gender (m:f) | 11:7 | 8:8 | 12:8 | 11:7 | 0.9 |
Age (years) | 63 (57-71) | 65 (55-75) | 63 (55-70) | 70 (46-74) | 0.9 |
BMI (kg/m2) | 26 (24-28) | 24 (21-27) | 26 (23-27) | 25 (22-29) | 0.5 |
SAPS II | 37 (26-40) | 38 (29-51) | 38 (30-43) | 29 (21-35) | 0.04* |
APACHE II | 12 (9-15) | 16 (11-19) | 13 (9-15) | 8 (6-15) | 0.1 |
Medical:Surgical | 13:5 | 11:5 | 16:4 | 11:7 | |
Creatinine clearance (ml/min) | 8 2 (48-104) | 58 (36-103) | 65 (40-114) | 57 (40-119) | 0.8 |